Zealand Pharma A/S (OTCMKTS:ZLDPF) Posts Earnings Results, Beats Estimates By $0.19 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) posted its quarterly earnings results on Thursday. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.19, Zacks reports. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%. The firm had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $28.11 million.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF opened at $108.30 on Friday. Zealand Pharma A/S has a twelve month low of $67.58 and a twelve month high of $141.74. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $7.69 billion, a P/E ratio of -45.89 and a beta of 0.88. The firm’s 50-day moving average is $101.97 and its two-hundred day moving average is $113.60.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ZLDPF shares. JPMorgan Chase & Co. began coverage on Zealand Pharma A/S in a research note on Friday, November 8th. They set an “overweight” rating for the company. Cantor Fitzgerald upgraded Zealand Pharma A/S to a “strong-buy” rating in a research report on Tuesday, January 21st.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.